Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Getting Back Into CV?

Executive Summary

Merck’s recent sale of its consume health business to Bayer involved a side bet on a new class of antihypertensive, which could mark a return to cardiovascular for Merck.

You may also be interested in...

IMPROVE-IT Go-Ahead Gives Merck Temporary Reprieve On Vytorin

Large outcomes study of Vytorin (ezetimibe/simvastatin) is allowed to carry on, reassuring investors that significant safety problems are unlikely to emerge. The development coincides with release of full results from the outcomes trial HPS2-THRIVE, in which Merck’s niacin-containing Tredaptive proved unsafe as well as ineffective.

Another Low Blow For Raising HDL; Merck’s Tredaptive Fails Phase III Trial

With Tredaptive’s failure to meet the primary endpoint in the HPS2-THRIVE study, Merck announces it does not plan to seek regulatory approval of the niacin/laropiprant combination pill in the U.S.

Merck Continues Pursuit Of Cardiovascular Candidates With Theravance Partnership

The New Jersey-based big pharma continues to take shots on the cardiovascular goal, even after a string of failures in the space.

Related Content

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts